Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972763 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
A Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01972763: Completed Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration, sponsored by Northern California Retina Vitreous Associates.
NCT01972763 is a Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01972763, a Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
California
- Northern California Retina Vitreous Associates - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
What the finished NCT01972763 record still lists
NCT01972763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Recalcitrant Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01972763 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01972763 about?
NCT01972763 is a clinical study titled "Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.". The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the ...
What is the current status of trial NCT01972763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-10. Estimated completion is 2018-07.
What conditions does trial NCT01972763 study?
This clinical trial studies the following conditions: Recalcitrant Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT01972763?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01972763?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01972763 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01972763's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia